Cited 0 times in Scipus Cited Count

Oncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer

DC Field Value Language
dc.contributor.authorOh, SY-
dc.contributor.authorKim, YB-
dc.contributor.authorSuh, KW-
dc.date.accessioned2018-07-27T00:52:05Z-
dc.date.available2018-07-27T00:52:05Z-
dc.date.issued2017-
dc.identifier.issn0277-3732-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15571-
dc.description.abstractOBJECTIVE: To investigate the oncologic outcome of ypT1-2N0 mid and lower rectal cancer after chemoradiotherapy (CRT) compared with pT1-2N0 rectal cancer.
METHODS: We compared the oncologic outcome of patients with mid and lower rectal cancer who underwent preoperative CRT and who did not, between February 2005 and August 2012.
RESULTS: Compared with patients who did not receive preoperative CRT, patients who received preoperative CRT did not have significantly different clinicopathologic features except clinical stage and distal resection margin. The 5-year disease-free survival (DFS) rates were lower in patients who received preoperative CRT than those who did not (84.4% vs. 95.5%, P=0.029). Preoperative CRT was a prognostic factor affecting 5-year DFS in patients with pathologically proven stage T1N0 mid and lower rectal cancer (HR, 11.157: 95% CI, 1.735-71.762: P=0.011)
CONCLUSIONS:: ypT2N0 rectal cancer after neoadjuvant CRT showed shorter DFS compared with pT2N0 rectal cancer.
-
dc.formatapplication/pdf-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHPreoperative Care-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRectal Neoplasms-
dc.subject.MESHTreatment Outcome-
dc.titleOncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer-
dc.typeArticle-
dc.identifier.pmid26083556-
dc.contributor.affiliatedAuthor오, 승엽-
dc.contributor.affiliatedAuthor김, 영배-
dc.contributor.affiliatedAuthor서, 광욱-
dc.type.localJournal Papers-
dc.identifier.doi10.1097/COC.0000000000000196-
dc.citation.titleAmerican journal of clinical oncology-
dc.citation.volume40-
dc.citation.number5-
dc.citation.date2017-
dc.citation.startPage512-
dc.citation.endPage516-
dc.identifier.bibliographicCitationAmerican journal of clinical oncology, 40(5). : 512-516, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1537-453X-
dc.relation.journalidJ002773732-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
26083556.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse